Literature DB >> 7550309

Night blindness in Sorsby's fundus dystrophy reversed by vitamin A.

S G Jacobson1, A V Cideciyan, G Regunath, F J Rodriguez, K Vandenburgh, V C Sheffield, E M Stone.   

Abstract

Sorsby's fundus dystrophy (SFD) is an autosomal dominant retinal degeneration caused by mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) gene. Mechanisms of the visual loss in SFD, however, remain unknown. In a SFD family with a novel TIMP3 point mutation, we tested a hypothesis that their night blindness is due to a chronic deprivation of vitamin A at the level of the photoreceptors caused by a thickened membrane barrier between the photoreceptor layer and its blood supply. Vitamin A at 50,000 IU/d was administered orally. Within a week, the night blindness disappeared in patients at early stages of disease. Nutritional night blindness is thus part of the pathophysiology of this genetic disease and vitamin A supplementation can lead to dramatic restoration of photoreceptor function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7550309     DOI: 10.1038/ng0995-27

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  47 in total

Review 1.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Clinical features of a novel TIMP-3 mutation causing Sorsby's fundus dystrophy: implications for disease mechanism.

Authors:  M Clarke; K W Mitchell; J Goodship; S McDonnell; M D Barker; I D Griffiths; N McKie
Journal:  Br J Ophthalmol       Date:  2001-12       Impact factor: 4.638

3.  Overview. Predictive DNA testing in ophthalmology.

Authors:  D A Mackey
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

4.  Successful photodynamic therapy for subretinal neovascularisation due to Sorsby's fundus dystrophy: 1 year follow up.

Authors:  S C Wong; K C S Fong; N Lee; K Gregory-Evans; C Y Gregory-Evans
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

Review 5.  Retinoids for treatment of retinal diseases.

Authors:  Krzysztof Palczewski
Journal:  Trends Pharmacol Sci       Date:  2010-06       Impact factor: 14.819

6.  A novel TIMP3 mutation associated with a retinitis pigmentosa-like phenotype.

Authors:  Meghan J DeBenedictis; Yosef Gindzin; Enrico Glaab; Bela Anand-Apte
Journal:  Ophthalmic Genet       Date:  2020-07-27       Impact factor: 1.803

Review 7.  Two-photon microscopy: shedding light on the chemistry of vision.

Authors:  Yoshikazu Imanishi; Kerrie H Lodowski; Yiannis Koutalos
Journal:  Biochemistry       Date:  2007-08-03       Impact factor: 3.162

8.  Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.

Authors:  Artur V Cideciyan; Tomas S Aleman; Sanford L Boye; Sharon B Schwartz; Shalesh Kaushal; Alejandro J Roman; Ji-Jing Pang; Alexander Sumaroka; Elizabeth A M Windsor; James M Wilson; Terence R Flotte; Gerald A Fishman; Elise Heon; Edwin M Stone; Barry J Byrne; Samuel G Jacobson; William W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-22       Impact factor: 11.205

Review 9.  Molecular genetics of macular dystrophies.

Authors:  K Zhang; H Yeon; M Han; L A Donoso
Journal:  Br J Ophthalmol       Date:  1996-11       Impact factor: 4.638

Review 10.  Biochemical Measurements of Free Opsin in Macular Degeneration Eyes: Examining the 11-CIS Retinal Deficiency Hypothesis of Delayed Dark Adaptation (An American Ophthalmological Society Thesis).

Authors:  Anne Hanneken; Thomas Neikirk; Jennifer Johnson; Masahiro Kono
Journal:  Trans Am Ophthalmol Soc       Date:  2017-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.